Background: It is unclear whether warfarin treatment with high time in therapeutic range
(TTR) is as effective and safe as non-vitamin K antagonist oral anticoagulants (NOACs). It is …

Background The efficacy and safety of warfarin for stroke prevention in atrial fibrillation (AF)
depend on the time in the therapeutic range (TTR) with an international normalised ratio …

Background: Atrial fibrillation (AF) patients on a vitamin K antagonist (VKA) with time in
therapeutic range (TTR)≥ 70% are not recommended to switch to a direct oral anticoagulant …

Background Vitamin K antagonist (VKA) therapy remains the most common method of stroke
prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited …

Objectives This study aimed to investigate the efficacy and safety outcomes of patients with
atrial fibrillation (AF) compared between those taking warfarin and non-vitamin K antagonist …

Background: Warfarin is highly efficacious in reducing stroke risk in patients with atrial
fibrillation (AF). However, its safety and efficacy in stroke prevention is markedly influenced …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as
an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) patients. Some studies …

Background\Anticoagulation is used for stroke prophylaxis in non-valvular atrial fibrillation,
amongst other by use of the vitamin K antagonist, warfarin. Quality in warfarin therapy is …

Background When oral anticoagulation with adjusted-dose vitamin K antagonist (VKA) is
used, the quality of anticoagulation control (as reflected by the time in therapeutic range …

Aims The efficacy and safety of oral anticoagulation (OAC) using the vitamin K antagonists
(VKA) are closely associated with the quality of anticoagulation, reflected by time in …